Personal profile
Education
- 2009 Honorary Doctor of Medicine, National Taiwan University, Taiwan
- 1989-1991 Fellow in Medical Oncology. Washington Hospital Center, Washington, D.C.
- 1970 Maryland Medical License
- 1961 ECFMG (Examining Council for Foreign Medical Graduates)
- 1959-1960 Resident in Pathology,Quincy City Hospital, Quincy, Mass.
- 1957-1959 Intern; Resident; Chief Resident in Surgery, New England Hospital, Boston, Massachusetts
- 1956 M.D. Medical College of Taiwan University, Taipei, Taiwan, R.O.C
- 1955-1957 Intern and Fixed Intern in Surgery, National Taiwan University Hospital, Taipei, Taiwan, Republic of China
- Resident in Internal Medicine, George Washington University Hospital, Washington, D.C., Maryland
- Virginia Medical License
- Certification: Clinical Cytogenetics (American Board of Medical Genetics)
- Specialist in Internal Medicine, The Board of Physician Quality Assurance of the State of Maryland
- Bona Fide Member, Taipei Medical Association（12965）
- The Board of Medical Oncology of the Chinese Oncology Society (82014)
Experience
- Vice Dean, College of Medical Science and Technology, Taipei Medical University
- Superintendent, Taipei Cancer Center, Taipei Medical University
- 2017.05- Director, Taiwan Oncology Society, R.O.C.
- 2015.08- Director, Taiwan Lung Cancer Society, R.O.C.
- 2014.10- Board Member, Development Center for Biotechnology (DCB)
- 2014.06- Member of the Board of Supervisors, Taiwan Genomics and Genetic Society
- 2014.06- Board Member, The MJ Health Research Foundation
- 2013.08- Superintendent, Taipei Cancer Center, Taipei Medical University
- 2013.04- Member, The Tang Prize Selection Committee, Academia Sinica
- 2013.01- Board Member, National Health Research Institutes (NHRI)
- 2012- Member, Certificate Approval Committee, Quality improvement of cancer service, BHP, Minstry of Health and Welfare (MOHW)
- 2012- Member, Committee of Hepatitis and Liver Cancer Control and Prevention, MOHW
- 2012- Member, Council Unit of Policy of Chinese Medicine Industries, Committee on Chinese Medicine and Pharmacy, MOHW
- 2012- Member, Council Unit of Science and Technology, MOHW
- 2012- Member, Honorary Doctorate Program Review Committee, Taipei Medical University
- 2012- Member, United Biobank Management Committee, Taipei Medical University
- 2011- Deputy member, Human Subject Research Ethics Committee, Academia Sinica
- 2011- Chair Professor & Associate Dean, Medical Science & Technology College of Taipei Medical University
- 2010- General Director, Cancer Research Center, Taipei Medical University
- 2009- Honorary Vice Superintendent, Taipei Medical University-Shangho Hospital, MOHW
- 2009- Adjunct Professor, Graduate Institute of Oncology, National Taiwan University
- 2008- Distinguished Research Fellow, Taipei Veterans General Hospital, Taiwan
- 2008- Physician, Hematology & Oncology, Taipei Medical University-Municipal Wan Fang Hospital
- 1998- Member, Academic Review Committee Ministry of Education, Executive Yuan
- 1997- Vice President, Formosa Cancer Foundation
Awards
- 1968 Woman of the Year Award, ROC
- 1972 Arthur Flemming Award, USA
- 1972 Honor Award from Department of Health, Education and Welfare, USA
- 1984 Academician, Academia Sinica, ROC
- 1985 Member, Advisory Committee, Institute of Biomedical Sciences, Academia Sinica
- 1985 Scientific Award & President, Chinese American Medical and Health Asso., USA
- 1989 Scientific Award, Chinese American Medical Society of USA
- 1989 Outstanding Scientific Award, Organization of Chinese Americans, USA
- 1989 PHS Commendation Award, USA
- 1990-1995 Advisory Member, Institute of Biomedical Sciences, Academia Sinica
- 1991-2008 Honorary Consultant, Veterans General Hospital-Taipei
- 1992-1994 Advisory Member, Institute of Zoology, Academia Sinica
- 1993-1996 Honorary Consultant, National Taiwan University Hospital
- 1993-1998 Advisory Member, Atomic Energy Council, Executive Yuan
- 1994 Advisory Member, Institute of Molecular Biology, Academia Sinica
- 1994-1998 Outstanding Scholarship Lecturer, Foundation for the Advanced Outstanding Scholarship
- 1995 Review Member, Personnel Committee, National Health Research Institutes
- 1995-1998 Advisory Member, AIDS Consultation Committee, Department of Health, Executive Yuan
- 1995-1997 President, the Chinese Oncology Society
- 1996-2007 Review Member, Recruitment and Advisory Committee, National Health Research Institutes
- 1996-2007 Review Member, Recruitment and Advisory Committee, Biostatistic Research Division, National Health Research Institutes
- 1996 Review Member, Yang Investigators’ Thesis Award, Academia Sinica
- 1996 Review Member, Research Physicians Grant, Institute of Biomedical Sciences, Academia Sinica
- 1996-1999 President, the Chinese Society of Genetics
- 1996-2009 Adjunct Professor, Medical College, National Taiwan University
- 1998-2001 President, The Chinese Society of Clinical Oncology,
- 2001-2007 Jacqueline Whang-Peng Honorary Lecturer (彭汪嘉康榮譽獎座)，National Tsing Hua University
- 2004-2006 Councilor, the Central Cancer Control Meeting, Executive Yuan
- 2007-2010 Chang-Chin Lecturer National Tsing Hua University
- 2008 Award for 1st L’OREAL Women for Science, Taiwan
- 2008 Distinguished Investigator, Emeritus, National Health Research Institutes
- 2009 Honorary Doctor of Medicine, National Taiwan University
- 2011 The 2011 Reach to Recovery International Health Professional Medal, UICC
- 2015 COS Lifetime Achievement Award, the Chinese Oncology Society, R.O.C
- 2015 Health Medal of the First Order, Ministry of Health and Welfare, R.O.C.
Research Interests
- Hemato-oncology
- Oncogenetics
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Projects
- 16 Finished
-
Integrin Αvβ3 Dependent Pathogenic Effect and Therapeutic Effects of Dl-N2 Derivatives Combined Egfr Inhibitors in Pancreatic Cancer
Whang-Peng, J. (PI)
8/1/23 → 7/31/24
Project: A - Government Institution › b - National Science and Technology Council
-
To Establish Clinical Connection of Integrin Αvβ3-Network and Ceacam6 as Progressing Detection Biomarkers and Therapeutic Targets in Cholangiocarcinoma Patient.( III )
Whang-Peng, J. (PI)
8/1/23 → 7/31/24
Project: A - Government Institution › b - National Science and Technology Council
-
To Establish Clinical Connection of Integrin Αvβ3-Network and Ceacam6 as Progressing Detection Biomarkers and Therapeutic Targets in Cholangiocarcinoma Patient.( II )
Whang-Peng, J. (PI)
8/1/22 → 7/31/23
Project: A - Government Institution › b - National Science and Technology Council
-
To Establish Clinical Connection of Integrin Αvβ3-Network and Ceacam6 as Progressing Detection Biomarkers and Therapeutic Targets in Cholangiocarcinoma Patient.( I )
Whang-Peng, J. (PI)
8/1/21 → 7/31/22
Project: A - Government Institution › b - National Science and Technology Council
-
Nano-Hevnp Theranostic Strategy for Late-Stage Colorectal Cancer Patients( III )
Whang-Peng, J. (PI)
8/1/21 → 7/31/22
Project: A - Government Institution › b - National Science and Technology Council
-
Integrin αvβ3-dependent pathogenic effect and therapeutic effects of DL-N2 combined with EGFR inhibitors in pancreatic adenocarcinoma
Li, Z. L., Kumar, S., Yang, S. N., Chang, T. C., Huang, L. Y., Ko, C. C., Yang, Y. N., Yao, C. J., Crawford, D. R., Gionfra, F., Solomon, D. D., Lee, Y. K., Xuan, D. T. M., Lin, H. R., Wang, C. Y., Aher, A., Abhista, N. B., Shih, Y. J., Lee, S. Y. & Huang, H. M. & 3 others, , Dec 2026, In: Journal of Translational Medicine. 24, 1, 321.Research output: Contribution to journal › Article › peer-review
Open Access -
Integrin αvβ3 is a Potential Therapeutic Target in Cholangiocarcinoma
Wulandari, F. S., Wang, C. Y., Crawford, D. R., Yang, Y. N., Then, C. K., Kumar, S., Suk, F. M., Huang, L. Y., Yang, Y. C. S. H., Li, Z. L., Shih, Y. J., Tu, H. T., Wang, K., Phu, H. D., Lin, C. M., Xuan, D. T. M., Solomon, D. D., Lin, H. Y. & Whang-Peng, J., 2026, In: International Journal of Medical Sciences. 23, 3, p. 889-915 27 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Correction to: Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients (Biomarker Research, (2025), 13, 1, (7), 10.1186/s40364-024-00715-5)
Cheng, T. C., Hung, M. C., Wang, L. H., Tu, S. H., Wu, C. H., Yen, Y., Chen, C. L., Whang-Peng, J., Lee, W. J., Liao, Y. C., Lee, Y. C., Pan, M. H., Lin, H. K., Tzeng, H. E., Guo, P., Chu, C. Y., Chen, L. C. & Ho, Y. S., Dec 2025, In: Biomarker Research. 13, 1, 100.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Heteronemin suppresses EGF‑induced proliferation through the PI3K/PD‑L1 signaling pathways in cholangiocarcinoma
Yang, Y. C. S. H., Tsai, C. C., Yang, Y. N., Liu, F. C., Lee, S. Y., Yang, J. C., Crawford, D. R., Chiu, H. C., Lu, M. C., Li, Z. L., Chen, Y. C., Chu, T. Y., Whang-Peng, J., Lin, H. Y. & Wang, K., Mar 2025, In: Oncology Reports. 53, 3, 32.Research output: Contribution to journal › Article › peer-review
1 Link opens in a new tab Citation (Scopus) -
Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients
Cheng, T.-C., Hung, M.-C., Wang, L.-H., Tu, S.-H., Wu, C.-H., Yen, Y., Chen, C.-L., Whang-Peng, J., Lee, W.-J., Liao, Y.-C., Lee, Y.-C., Pan, M.-H., Lin, H.-K., Tzeng, H.-E., Guo, P., Chu, C.-Y. & Chen, L.-C., Jan 9 2025, In: Biomarker Research. 13, 1, p. 7 7.Research output: Contribution to journal › Article › peer-review
Open Access3 Link opens in a new tab Citations (Scopus)
Datasets
-
Active fraction (HS7) from Taiwanofungus camphoratus inhibits AKT-mTOR, ERK and STAT3 pathways and induces CDK inhibitors in CL1-0 human lung cancer cells
Lai, I.-C. (Contributor), Lai, G.-M. (Contributor), Chow, J.-M. (Contributor), Lee, H.-L. (Contributor), Yeh, C.-F. (Creator), Li, C.-H. (Contributor), Yan, J.-L. (Contributor), Chuang, S.-E. (Contributor), Whang-Peng, J. (Creator), Bai, K.-J. (Contributor) & Yao, C.-J. (Contributor), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3931717.v1, https://doi.org/10.6084%2Fm9.figshare.c.3931717.v1
Dataset
-
Supplementary Material for: The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme
Lee, P.-Y. (Creator), Chen, C.-L. (Creator), Lin, Z.-Z. (Creator), Cheng, A.-L. (Creator), Chen, E.I.-T. (Creator), Whang-Peng, J. (Creator) & Huang, C.-Y. F. (Contributor), Karger Publishers, 2013
DOI: 10.6084/m9.figshare.5124601.v1, https://karger.figshare.com/articles/dataset/Supplementary_Material_for_The_Aurora_Kinases_Inhibitor_VE-465_is_a_Novel_Treatment_for_Glioblastoma_Multiforme/5124601/1
Dataset
-
MOESM3 of Active fraction (HS7) from Taiwanofungus camphoratus inhibits AKT-mTOR, ERK and STAT3 pathways and induces CDK inhibitors in CL1-0 human lung cancer cells
Whang-Peng, J. (Creator), Chow, J.-M. (Contributor), Yan, J.-L. (Contributor), Lee, H.-L. (Contributor), Yeh, C.-F. (Creator), Lai, I.-C. (Contributor), Yao, C.-J. (Contributor), Lai, G.-M. (Contributor), Bai, K.-J. (Contributor), Chuang, S.-E. (Contributor) & Li, C.-H. (Contributor), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3931717_d3.v1, https://doi.org/10.6084%2Fm9.figshare.c.3931717_d3.v1
Dataset
-
Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways
Huang, Y.-J. (Contributor), Yang, C.-K. (Contributor), Wei, P.-L. (Contributor), Huynh, T.-T. (Contributor), Whang-Peng, J. (Creator), Meng, T.-C. (Contributor), Hsiao, M. (Creator), Tzeng, Y.-M. (Contributor), Wu, A. T. (Creator) & Yen, Y. (Creator), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3704533.v1, https://doi.org/10.6084%2Fm9.figshare.c.3704533.v1
Dataset
-
Additional file 2: Figure S1. of Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways
Huynh, T.-T. (Contributor), Tzeng, Y.-M. (Contributor), Yen, Y. (Creator), Yang, C.-K. (Contributor), Wu, A. T. (Creator), Meng, T.-C. (Contributor), Whang-Peng, J. (Creator), Wei, P.-L. (Contributor), Hsiao, M. (Creator) & Huang, Y.-J. (Contributor), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3704533_d1.v1, https://doi.org/10.6084%2Fm9.figshare.c.3704533_d1.v1
Dataset